Randomised controlled trialindependent cross-checkabstract checked I-UPF-114 in-depth review
Emulsifiers in people with Crohn's disease
Clinical Trial: The Effects of Emulsifiers in the Food Supply on Disease Activity in Crohn's Disease: An Exploratory Double-Blinded Randomised Feeding Trial.
Overview
Fitzpatrick JA et al.. Aliment Pharmacol Ther 2025 · PMID 39967287 · DOI 10.1111/apt.70041
In a small blinded trial, a diet high in food emulsifiers did not worsen Crohn's disease over four weeks compared with a low-emulsifier diet.
Does the study support the specific claim? No · Methodological quality: moderate
Plain-language summary
Study explained simply
- What did the researchers want to find out?
To test whether food emulsifiers worsen Crohn's disease.
- How was the study done?
Double-blinded randomised feeding trial.
- How many people, animals or samples were studied?
24 patients.
- What was actually found?
No difference between diets; both improved.
- How large was the observed effect?
Remission 9/12 vs 7/12.
- What do the results mean in everyday life?
Avoiding emulsifiers is not proven to help Crohn's disease.
- What are the study's limitations?
Small and short.
- What does it say about Elawady's specific claim?
Contradicts C-UPF-06 in humans.
- Do the results apply to Germany and Europe?
Applicable.
- What can explicitly not be concluded from this study?
Cannot exclude long-term or dose-specific effects.
Scientific in-depth review
1. Full reference
- Authors
- Fitzpatrick JA et al.
- Journal
- Aliment Pharmacol Ther
- Year
- 2025
- Identifier
- PMID 39967287 DOI 10.1111/apt.70041 · PMC11950802
- Verification
- verified – PubMed efetch 2026-10-26; Crossref works API 2026-10-26
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
COI statement in record: first author speaker honoraria from Mindset Health and PepsiCo; co-author advisory roles; funding: NHMRC, Crohn's and Colitis Australia, Crohn's and Colitis Foundation, Eva and Tom Breuer Foundation.
2. Research question
Do diets high vs low in food-supply emulsifiers affect disease activity in Crohn's disease?
3. Study design and population
- Study design
- Randomised controlled trial – Exploratory double-blinded randomised feeding trial
- Population
Adults with symptomatic, sonographically active ileal CD on stable therapy
- Country
Australia
- Period
Registered ACTRN12619001099112
- Sample size
24 randomised
- Inclusion and exclusion criteria
Active ileal CD, stable therapy >=2 months
4. Methods and endpoints
- Exposure / intervention
High-emulsifier diet (HED) for 4 weeks
- Comparator
Low-emulsifier diet (LED), both modelled on healthy eating guidelines
- Endpoints
Harvey-Bradshaw Index, intestinal ultrasound activity, bowel wall thickness, QoL, fatigue
- Statistical methods
Between-group comparisons
5. Actual results
- Results
Clinical remission 9/12 (HED) vs 7/12 (LED); IBUS-SAS fell on both (HED 51 to 33, P=0.014; LED 57 to 44, P=0.01); bowel wall thickness reduced 34% (HED) and 15% (LED) in completers; QoL and fatigue improved on both; no statistically significant differences between diets. Adherence >95%.
- Absolute risks
Remission 75% vs 58% (not significant)
- Authors' conclusion
In the context of a healthy diet, emulsifier content had no influence on disease activity over 4 weeks in CD; recommendations to avoid emulsifiers in active CD are not supported.
6. Strengths
- Double-blinded, controlled feeding
- Patients most likely to be affected
7. Weaknesses
- Exploratory, 24 patients
- 4 weeks only
8. Risk of bias
- Orienting tool
- RoB 2
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- some concerns
- Rationale
Small exploratory trial; low power.
9. Assessment of the statistical interpretation
Underpowered; effects point if anything toward HED, not harm.
10. Relevance to the specific claim
Direct human test in a susceptible group: no harm from usual emulsifier levels over 4 weeks.
11. Independent contrary findings
Too small to exclude modest effects.
12. Transferability to Germany and Europe
Applicable.
13. Overall methodological judgement
Contradicts strong claims of emulsifier-driven inflammation in humans at usual intake.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | moderate |
| Risk of bias | some concerns |
| Precision of results | low |
| Directness | direct |
| Reproducibility | not replicated |
| Consistency with the overall evidence | mixed |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
Larger, longer trials (e.g. specific emulsifiers like CMC).
15. Linked fact checks
- Industrial emulsifiers such as carboxymethylcellulose erode the gut's protective mucus layer and drive inflammation and metabolic disease. – Studies contradicting or limiting the claim